Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences (NASDAQ: DRUG) will present at three investor conferences in early March 2026: TD Cowen (Mar 4), Leerink Partners (Mar 9), and Jefferies Biotech on the Beach (Mar 10).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bright Minds Biosciences (NASDAQ: DRUG) will present at three investor conferences in early March 2026: TD Cowen (Mar 4), Leerink Partners (Mar 9), and Jefferies Biotech on the Beach (Mar 10).
The TD Cowen presentation will be webcast live and archived; the replay will be available for 60 days and accessible via the company’s investor site.
Details
News Market Reaction – DRUG
On Feb 26, the first trading day after this news, DRUG closed 5.00% below the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
Key Figures
- TD Cowen conference date
- March 4, 2026
- TD Cowen 46th Annual Health Care Conference
- TD Cowen presentation time
- 9:10am ET
- Company presentation slot
- Leerink conference date
- March 9, 2026
- Leerink Partners 2026 Global Healthcare Conference
- Jefferies conference date
- March 10, 2026
- Jefferies 2026 Biotech on the Beach
- Webcast replay period
- 60 days
- Availability of TD Cowen conference replay
Historical Context
-
Announced timing of Labcorp’s Q4 2025 financial results release and call.
-
Closed US$175.05M public offering of 1,945,000 shares at US$90.00.
-
Priced upsized US$175.05M equity offering at US$90.00 per share.
-
Launched US$100M public offering to fund clinical trials and R&D.
-
Reported positive Phase 2 results for BMB-101 in absence seizures and DEE.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:
| EVENT: | TD Cowen 46th Annual Health Care Conference |
| DATE: | Wednesday, March 4, 2026 |
| TIME: | 9:10am ET |
| WEBCAST: | https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/cy8oQuZ2XnJiLiEqXopBn7 |
| EVENT: | Leerink Partners 2026 Global Healthcare Conference |
| DATE: | Monday, March 9, 2026 |
| WEBCAST: | No webcast |
| EVENT: | Jefferies 2026 Biotech on the Beach |
| DATE: | Tuesday, March 10, 2026 |
| DETAILS: | 1x1’s with management; please contact your Jefferies sales representative to schedule a meeting. |
The live and archived webcast for the Cowen event will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 60 days.
About Bright Minds Biosciences
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Contact Information
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.